Cite
HARVARD Citation
Borghaei, H. et al. (n.d.). 359 AMG 757, a half-life extended bispecific T-cell engager (BiTE®) immune therapy against DLL3 in SCLC: phase 1 interim results. Journal for immunotherapy of cancer. p. A384. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Borghaei, H. et al. (n.d.). 359 AMG 757, a half-life extended bispecific T-cell engager (BiTE®) immune therapy against DLL3 in SCLC: phase 1 interim results. Journal for immunotherapy of cancer. p. A384. [Online].